Publications

G9a regulates group 2 innate lymphoid cell development by repressing the group 3 innate lymphoid cell program.

Authors: F Antignano, M Braam, MR Hughes, AL Chenery, K Burrows, MJ Gold, MJ Oudhoff...

E-pub date: 27 Jun 2016

Journal name: J Exp Med

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

Authors: B Pereira, S-F Chin, OM Rueda, H-KM Vollan, E Provenzano, HA Bardwell, M Pu...

E-pub date: 6 Jun 2016

Journal name: Nat Commun

DNA REPAIR. Drugging DNA repair.

Authors: SP Jackson, T Helleday

E-pub date: 3 Jun 2016

Journal name: Science

DIFFERENTIAL RESPONSES OF MURINE MODELS OF SUPRATENTORIAL EPENDYMOMA TO GEMCITABINE AS MEASURED BY MRI AND PET-CT

Authors: N Boulos, J Kim, Z Patay, ER Butch, M Ayaz, SE Snyder, C Calabrese, RJ Gilb...

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES – AN EXAMPLE OF BRAIN TUMOUR THERAPY

Authors: B Nimmervoll, Y Patel, B Bianski, M DeCuypere, A Shelat, C Stewart, T Merch...

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS

Authors: Y Tong, D Merino, B Nimmervoll, K Gupta, D Finkelstein, DW Ellison, J Zang,...

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

ACCURATE PRECLINICAL TRIALS OF NEW EPENDYMOMA THERAPIES

Authors: N Boulos, J Dapper, Y Patel, M DeCuypere, B Bianski, T Merchant, B Freeman,...

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

MEDULLOBLASTOMA GENOTYPE DICTATES BLOOD BRAIN BARRIER PHENOTYPE

Authors: T Phoenix, D Patmore, S Boop, N Boulos, M Jacus, Y Patel, M Roussel, D Fink...

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

Filters

Research Groups

Core Facilities

Start date

End date

G9a regulates group 2 innate lymphoid cell development by repressing the group 3 innate lymphoid cell program.

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

DNA REPAIR. Drugging DNA repair.

DIFFERENTIAL RESPONSES OF MURINE MODELS OF SUPRATENTORIAL EPENDYMOMA TO GEMCITABINE AS MEASURED BY MRI AND PET-CT

A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES – AN EXAMPLE OF BRAIN TUMOUR THERAPY

NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS

ACCURATE PRECLINICAL TRIALS OF NEW EPENDYMOMA THERAPIES

MEDULLOBLASTOMA GENOTYPE DICTATES BLOOD BRAIN BARRIER PHENOTYPE

Themes

Filters

Research Groups

Core Facilities

Start date

End date

G9a regulates group 2 innate lymphoid cell development by repressing the group 3 innate lymphoid cell program.

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

DNA REPAIR. Drugging DNA repair.

DIFFERENTIAL RESPONSES OF MURINE MODELS OF SUPRATENTORIAL EPENDYMOMA TO GEMCITABINE AS MEASURED BY MRI AND PET-CT

A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES – AN EXAMPLE OF BRAIN TUMOUR THERAPY

NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS

ACCURATE PRECLINICAL TRIALS OF NEW EPENDYMOMA THERAPIES

MEDULLOBLASTOMA GENOTYPE DICTATES BLOOD BRAIN BARRIER PHENOTYPE